{"id":"voquezna-triple-pak","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Taste perversion"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":{"setId":"0cb2ee04-8581-46c8-a781-7be170ab5c86","title":"VOQUEZNA DUAL PAK (VONOPRAZAN FUMARATE AND AMOXICILLIN) KIT VOQUEZNA TRIPLE PAK (VONOPRAZAN FUMARATE, AMOXICILLIN AND CLARITHROMYCIN) KIT [PHATHOM PHARMACEUTICALS INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vonoprazan is a potassium-competitive acid blocker (PCAB) that provides rapid and sustained gastric acid suppression, creating an optimal environment for the antibiotics amoxicillin and clarithromycin to eliminate H. pylori infection. This triple combination approach targets the bacterium through both acid reduction and direct antimicrobial activity, improving eradication rates compared to traditional proton pump inhibitor-based regimens.","oneSentence":"VOQUEZNA Triple Pak is a combination therapy containing vonoprazan (a potassium-competitive acid blocker) plus amoxicillin and clarithromycin that eradicates Helicobacter pylori by suppressing gastric acid and delivering dual antibiotics.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:15:53.897Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori eradication in adults"}]},"trialDetails":[{"nctId":"NCT07224035","phase":"PHASE4","title":"Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2022-10-15","conditions":"H Pylori Infection, H Pylori Gastritis, Gastric Cancer","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"VOQUEZNA® Triple Pak®","genericName":"VOQUEZNA® Triple Pak®","companyName":"University of Miami","companyId":"university-of-miami","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VOQUEZNA Triple Pak is a small molecule treatment used for Helicobacter Pylori Infection, Helicobacter Pylori Gastritis, and Gastric Cancer, as indicated by ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-05-03T00:00:00.000Z","mah":"PHATHOM","brand_name_local":"VOQUEZNA TRIPLE PAK","application_number":"NDA215152"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}